Compounds for the treatment of neurodegenerative diseases

• US 10,538,553 B2
• Filed: 01/04/2019
• Issued: 01/21/2020
• Est. Priority Date: 01/05/2018
• Status: Active Grant

• Current Assignee: University of South Florida (State University System of Florida)
• Original Assignee: University of South Florida (State University System of Florida)
• Inventors: Cai, Jianfeng, Cao, Chuanhai
• Primary Examiner(s): Weidner, Adam
• Application Number:
  US16/240,673
• Publication Number:
  US 20190211059A1
• Time in Patent Office: 382 Days
• Field of Search: None
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C07K 7/02 Linear peptides containing at least one abnormal peptide link

Abstract

Disclosed herein are compounds for the treatment of neurodegenerative diseases and compositions comprising the same.

Claims

1. A compound selected from the following:

2. A pharmaceutical composition comprising the compound or salt of claim 1, and a carrier.

3. A method of treating a neurodegenerative disease in a subject, the method comprising administering to the subject the compound or salt of claim 1, wherein the neurodegenerative disease is selected from Alzheimer'"'"'s Disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson'"'"'s Disease (PD), Huntington'"'"'s Disease, prion disease, motor neuron disease, spinocerebellar ataxia, spinal muscular atrophy, primary age-related tauopathy (PART)/Neurofibrillary tangle-predominant senile dementia, chronic traumatic encephalopathy, dementia pugilistica, dementia with Lewy bodies, neuroaxonal dystrophies, multiple system atrophy, progressive supranuclear palsy, Pick'"'"'s Disease, corticobasal degeneration, frontotemporal dementia with parkinsonism linked to chromosome 17, Lytico-Bodig disease (Parkinson-dementia complex of Guam), ganglioglioma, gangliocytoma, meningioangiomatosis, postencephalitic parkinsonism, subacute sclerosing panencephalitis, lead encephalopathy, tuberous sclerosis, Hallervorden-Spatz disease, and lipofuscinosis.

4. The method of claim 3, wherein the neurodegenerative disease is selected from Alzheimer'"'"'s Disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson'"'"'s Disease (PD), and Huntington'"'"'s Disease.

5. The method of claim 3, wherein the neurodegenerative disease is Alzheimer'"'"'s Disease (AD).

6. A method of reducing or eliminating an aggregated protein in a subject, the method comprising administering to the subject the compound or salt of claim 1, wherein the aggregated protein comprises at least one of tau, synuclein, amyloid-beta, or a combination thereof.

7. The method of claim 6, wherein the synuclein is alpha-synuclein.

8. A method of reducing or inhibiting protein aggregation in a subject, the method comprising administering to the subject an effective amount of the compound or salt of claim 1, wherein the protein comprises at least one of tau, synuclein, amyloid-beta, or a combination thereof.

9. The method of claim 8, wherein the synuclein is alpha-synuclein.